Perrigo PE Ratio 2012-2025 | PRGO
Current and historical p/e ratio for Perrigo (PRGO) from 2012 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Perrigo PE ratio as of February 06, 2026 is 5.05.
| Perrigo PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-02-06 | 14.64 | 0.00 | |
| 2025-09-30 | 21.79 | $-0.38 | 0.00 |
| 2025-06-30 | 25.82 | $-0.58 | 0.00 |
| 2025-03-31 | 26.81 | $-1.31 | 0.00 |
| 2024-12-31 | 24.33 | $-1.25 | 0.00 |
| 2024-09-30 | 24.59 | $-1.17 | 0.00 |
| 2024-06-30 | 23.84 | $-0.92 | 0.00 |
| 2024-03-31 | 29.59 | $-0.07 | 0.00 |
| 2023-12-31 | 29.29 | $-0.10 | 0.00 |
| 2023-09-30 | 28.82 | $0.05 | 576.35 |
| 2023-06-30 | 30.39 | $-0.42 | 0.00 |
| 2023-03-31 | 31.83 | $-0.96 | 0.00 |
| 2022-12-31 | 30.03 | $-0.96 | 0.00 |
| 2022-09-30 | 31.16 | $-0.63 | 0.00 |
| 2022-06-30 | 35.20 | $-0.70 | 0.00 |
| 2022-03-31 | 33.13 | $-0.65 | 0.00 |
| 2021-12-31 | 33.29 | $-0.35 | 0.00 |
| 2021-09-30 | 40.23 | $-1.88 | 0.00 |
| 2021-06-30 | 38.74 | $-2.57 | 0.00 |
| 2021-03-31 | 34.02 | $-1.70 | 0.00 |
| 2020-12-31 | 37.38 | $-1.21 | 0.00 |
| 2020-09-30 | 38.19 | $-0.06 | 0.00 |
| 2020-06-30 | 45.78 | $1.74 | 26.31 |
| 2020-03-31 | 39.67 | $1.37 | 28.96 |
| 2019-12-31 | 42.46 | $1.07 | 39.68 |
| 2019-09-30 | 45.75 | $1.81 | 25.27 |
| 2019-06-30 | 38.80 | $0.65 | 59.70 |
| 2019-03-31 | 39.06 | $0.84 | 46.50 |
| 2018-12-31 | 31.30 | $0.94 | 33.30 |
| 2018-09-30 | 57.02 | $0.86 | 66.30 |
| 2018-06-30 | 58.57 | $1.66 | 35.28 |
| 2018-03-31 | 66.78 | $0.91 | 73.39 |
| 2017-12-31 | 69.68 | $0.84 | 82.95 |
| 2017-09-30 | 67.55 | $-9.16 | 0.00 |
| 2017-06-30 | 60.14 | $-18.23 | 0.00 |
| 2017-03-31 | 52.76 | $-16.39 | 0.00 |
| 2016-12-31 | 66.00 | $-19.23 | 0.00 |
| 2016-09-30 | 73.09 | $-10.49 | 0.00 |
| 2016-06-30 | 71.66 | $-0.96 | 0.00 |
| 2016-03-31 | 100.96 | $-1.93 | 0.00 |
| 2015-12-31 | 114.07 | $-0.26 | 0.00 |
| 2015-09-30 | 123.87 | $0.99 | 125.12 |
| 2015-06-30 | 145.47 | $0.94 | 154.76 |
| 2015-03-31 | 130.22 | $0.56 | 232.53 |
| 2014-12-31 | 131.38 | $1.59 | 82.63 |
| 2014-09-30 | 117.96 | $0.21 | 561.71 |
| 2014-06-30 | 114.40 | $0.67 | 170.74 |
| 2014-03-31 | 121.29 | $0.67 | 181.03 |
| 2013-12-31 | 120.27 | $1.49 | 80.72 |
| 2013-09-30 | 96.63 | $3.48 | 27.77 |
| 2013-06-30 | 94.70 | $3.42 | 27.69 |
| 2013-03-31 | 92.86 | $3.42 | 27.15 |
| 2012-12-31 | 81.29 | $3.47 | 23.43 |
| 2012-09-30 | 90.70 | $3.41 | 26.60 |
| 2012-06-30 | 92.00 | $3.04 | 30.26 |
| 2012-03-31 | 80.54 | $3.04 | 26.49 |
| 2011-12-31 | 75.79 | $2.76 | 27.46 |
| 2011-09-30 | 75.57 | $2.67 | 28.31 |
| 2011-06-30 | 68.33 | $2.72 | 25.12 |
| 2011-03-31 | 61.79 | $2.72 | 22.72 |
| 2010-12-31 | 49.16 | $2.43 | 20.23 |
| 2010-09-30 | 49.80 | $2.01 | 24.77 |
| 2010-06-30 | 45.75 | $1.87 | 24.47 |
| 2010-03-31 | 45.43 | $1.87 | 24.29 |
| 2009-12-31 | 30.78 | $1.70 | 18.10 |
| 2009-09-30 | 26.22 | $1.42 | 18.47 |
| 2009-06-30 | 21.39 | $1.16 | 18.44 |
| 2009-03-31 | 19.08 | $1.16 | 16.45 |
| 2008-12-31 | 24.76 | $1.09 | 22.72 |
| 2008-09-30 | 29.43 | $1.18 | 24.94 |
| 2008-06-30 | 24.27 | $1.14 | 21.29 |
| 2008-03-31 | 28.78 | $1.14 | 25.25 |
| 2007-12-31 | 26.67 | $0.90 | 29.63 |
| 2007-09-30 | 16.24 | $0.77 | 21.09 |
| 2007-06-30 | 14.86 | $0.60 | 24.77 |
| 2007-03-31 | 13.37 | $0.60 | 22.29 |
| 2006-12-31 | 13.07 | $0.64 | 20.42 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $2.015B | $4.373B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $192.719B | 21.52 |
| EssilorLuxottica (ESLOY) | France | $140.970B | 0.00 |
| Stryker (SYK) | United States | $137.019B | 26.29 |
| Medtronic (MDT) | Ireland | $131.919B | 18.28 |
| Boston Scientific (BSX) | United States | $113.066B | 25.01 |
| Medline (MDLN) | United States | $62.139B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $46.969B | 0.00 |
| ResMed (RMD) | United States | $39.571B | 26.42 |
| GE HealthCare Technologies (GEHC) | United States | $36.756B | 17.61 |
| Agilent Technologies (A) | United States | $36.736B | 23.22 |
| Koninklijke Philips (PHG) | Netherlands | $28.368B | 18.53 |
| Terumo (TRUMY) | Japan | $19.441B | 21.97 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.819B | 11.11 |
| Insulet (PODD) | United States | $17.019B | 52.82 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.739B | 0.00 |
| Baxter (BAX) | United States | $11.170B | 9.02 |
| Sunny Optical Technology (SNPTF) | China | $8.485B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.133B | 29.24 |
| Demant (WILYY) | Denmark | $6.521B | 0.00 |
| Envista Holdings (NVST) | United States | $4.785B | 24.25 |
| Lantheus Holdings (LNTH) | United States | $4.303B | 13.11 |
| BillionToOne (BLLN) | United States | $4.147B | 0.00 |
| ICU Medical (ICUI) | United States | $3.806B | 24.16 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.263B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.139B | 14.81 |
| Haemonetics (HAE) | United States | $2.758B | 12.06 |
| Neogen (NEOG) | United States | $2.349B | 51.43 |
| Phibro Animal Health (PAHC) | United States | $2.151B | 18.95 |
| LeMaitre Vascular (LMAT) | United States | $1.983B | 39.92 |
| QuidelOrtho (QDEL) | United States | $1.977B | 12.71 |
| AtriCure (ATRC) | United States | $1.845B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.622B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.486B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.475B | 64.64 |
| AdaptHealth (AHCO) | United States | $1.442B | 20.88 |
| Capricor Therapeutics (CAPR) | United States | $1.130B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.080B | 320.43 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.021B | 0.00 |
| InMode (INMD) | Israel | $0.953B | 10.77 |
| Tilray Brands (TLRY) | Canada | $0.883B | 0.00 |
| Valneva SE (VALN) | France | $0.817B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.803B | 0.00 |
| Omeros (OMER) | United States | $0.796B | 0.00 |
| CeriBell (CBLL) | United States | $0.747B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.587B | 15.91 |
| Verano Holdings (VRNO) | United States | $0.454B | 0.00 |
| Brainsway (BWAY) | Israel | $0.427B | 72.60 |
| Cerus (CERS) | United States | $0.423B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.405B | 0.00 |
| SNDL (SNDL) | Canada | $0.389B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.377B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.328B | 26.18 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.309B | 0.00 |
| Evolus (EOLS) | United States | $0.292B | 0.00 |
| Quanterix (QTRX) | United States | $0.284B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.237B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.222B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| TerrAscend (TSNDF) | Canada | $0.208B | 0.00 |
| Organigram Global (OGI) | Canada | $0.207B | 0.00 |
| High Tide (HITI) | Canada | $0.207B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.197B | 17.71 |
| Aurora Cannabis (ACB) | Canada | $0.197B | 58.00 |
| OraSure Technologies (OSUR) | United States | $0.194B | 0.00 |
| Accendra Health (ACH) | United States | $0.185B | 1.85 |
| Sanara MedTech (SMTI) | United States | $0.180B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.179B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Apyx Medical (APYX) | United States | $0.148B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.144B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.136B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.72 |
| MacroGenics (MGNX) | United States | $0.115B | 0.00 |
| Biote (BTMD) | United States | $0.102B | 4.46 |
| Jushi Holdings (JUSHF) | United States | $0.100B | 0.00 |
| Exagen (XGN) | United States | $0.080B | 0.00 |
| ImmuCell (ICCC) | United States | $0.056B | 24.00 |
| Sharps Technology (STSS) | United States | $0.048B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.042B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.042B | 0.00 |
| Nephros (NEPH) | United States | $0.041B | 29.77 |
| Veru (VERU) | United States | $0.038B | 0.00 |
| Modular Medical (MODD) | United States | $0.034B | 0.00 |
| United-Guardian (UG) | United States | $0.033B | 16.63 |
| Jin Medical (ZJYL) | China | $0.022B | 0.00 |
| Bonk (BNKK) | United States | $0.021B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| INLIF (INLF) | China | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Agape ATP (ATPC) | $0.002B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |